Home » BAXTER AND JERINI ADVANCE PROGRAM TO DEVELOP NON-INTRAVENOUS HEMOPHILIA THERAPY
BAXTER AND JERINI ADVANCE PROGRAM TO DEVELOP NON-INTRAVENOUS HEMOPHILIA THERAPY
Baxter AG and Jerini AG today announced progress in their collaborative research program to develop a non-intravenous therapy for the treatment of hemophilia. Extensive in vitro and in vivo analyses have identified several synthetic lead molecules with promising pharmacological properties.
Europa Press
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May